Whether progress will be made in the insurance reimbursement discussions for the ALK antitumor drug Lorviqua is gaining attention.

The health authorities recently said they would “promptly start discussions” on the need to expand coverage of the ALK-positive NSCLC drug Lorviqua (lorlatinib) to the first-line.

Lorviqua is currently in the process of terminating its risk-sharing agreement (RSA) and has applied for a general listing. Pfizer filed for the general listing shortly after the breakdown of drug price negotiations with the National Health Insurance Service in June, but there was little discussion made on the agenda until recently.

At the time, the NHIS said that t